Free tool
FAERS Monitor: Thiola Ec
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 211843 or its brand name (Thiola Ec, Tiopronin). Reports on generic versions are filed under their own applications.
Reports
900
Serious
341
38% of reports
Hospitalization
215
Death reported
53
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective286
- fatigue49
- pyrexia48
- rash48
- nausea45
- product dose omission issue36
- vomiting30
- flank pain26
- proteinuria26
- urinary tract infection26
- diarrhoea23
- dyspepsia21
- death20
- headache20
- pneumonia20
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 2 |
| 2005 | 4 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 6 |
| 2011 | 33 |
| 2012 | 34 |
| 2013 | 4 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 7 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 23 |
| 2020 | 36 |
| 2021 | 64 |
| 2022 | 134 |
| 2023 | 132 |
| 2024 | 147 |
| 2025 | 181 |
| 2026 | 86 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,259 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| flank painSignal | 26 | 65.0 | 44.5 | 1,572 |
| proteinuriaSignal | 26 | 32.0 | 21.9 | 750 |
| drug ineffectiveSignal | 286 | 5.1 | 4.6 | 993 |
| dyspepsiaSignal | 21 | 5.0 | 3.3 | 63 |
| urinary tract infectionSignal | 26 | 3.6 | 2.4 | 46 |
| pyrexiaSignal | 48 | 3.2 | 2.5 | 73 |
| product dose omission issueSignal | 36 | 2.9 | 2.1 | 42 |
| rashSignal | 48 | 2.6 | 2.0 | 46 |
| vomiting | 30 | 1.5 | 1.0 | 4 |
| fatigue | 49 | 1.5 | 1.1 | 7 |
| pneumonia | 20 | 1.4 | 0.9 | 2 |
| nausea | 45 | 1.3 | 1.0 | 3 |
| diarrhoea | 23 | 0.8 | 0.6 | 1 |
| headache | 20 | 0.7 | 0.5 | 2 |
| death | 20 | 0.5 | 0.4 | 8 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.